Lung transplants are the ultimate therapeutic strategy for many people with cystic fibrosis (CF) and other chronic lung diseases,…
Patricia Inácio, PhD
Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Patricia Inácio, PhD
Minimally Invasive Imaging Device Shows Changes in Nasal Airways, May Allow Earlier CF Diagnosis
A minimally invasive imaging device that generates high-resolution images of nasal airways, including the cilia and mucus, allows researchers to…
Using the CRISPR gene editing tool, a team of researchers was able to permanently correct two mutations in the CFTR…
Treatment for three years with Kalydeco (ivacaftor) reduces the risk of lung infection by serious pathogens — including Pseudomonas…
Treatment with Kalydeco (ivacaftor) improved lung function, exercise capacity, and sweat chloride concentration in cystic fibrosis (CF) patients with severe lung…
Long-term use of inhaled antibiotics, given to treat lung infections caused by the bacteria Pseudomonas aeruginosa in people with cystic…
Treatment with Orkambi significantly improves exercise tolerance in adult cystic fibrosis patients with severe disease as early as…
Data from Phase 1 studies in healthy people and preclinical work indicate that ELX-02 may help to treat cystic…
Nitric Oxide Shows Positive Signs in Clearing Hard-to-treat Mycobacterium Lung Infections in CF
Inhalation of nitric oxide as an add-on therapy may help reduce the burden of serious bacterial lung infections, namely the…
Kalydeco’s Safety and Benefits Maintained Long-term in 2-to-5-year-olds with CF, Phase 3 Trial Shows
Long-term treatment with Kalydeco (ivacaftor) is well-tolerated and efficient, with improvements in sweat chloride concentration, growth, and pancreas function…